Caribou Biosciences Inc (CRBU)

$1.31 -0.10 (-7.09%)
Market Cap 127.68M
Revenue (ttm) 34.48M
Net Income (ttm) -102.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -296.03%
Debt to Equity Ratio 0.00
Volume 784,200
Avg Vol 1,406,262
Day's Range N/A - N/A
Shares Out 90.55M
Stochastic %K 38%
Beta 2.31
Analysts Strong Sell
Price Target $13.25

Latest News on CRBU

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU

Feb 20, 2025, 1:28 PM EST - 2 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Feb 19, 2025, 10:22 AM EST - 3 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Caribou Biosciences to Participate in Upcoming Investor Conferences

Feb 18, 2025, 4:05 PM EST - 4 days ago

Caribou Biosciences to Participate in Upcoming Investor Conferences

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Feb 16, 2025, 7:33 AM EST - 6 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

Feb 15, 2025, 3:04 PM EST - 7 days ago

CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Jan 29, 2025, 10:51 AM EST - 24 days ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

Jan 13, 2025, 5:45 AM EST - 5 weeks ago

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

Jan 12, 2025, 7:05 PM EST - 5 weeks ago

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:00 PM EST - 6 weeks ago

Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

Dec 26, 2024, 6:23 PM EST - 2 months ago

Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Sep 30, 2024, 3:53 AM EDT - 5 months ago

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

Aug 12, 2024, 8:00 AM EDT - 6 months ago

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

Jul 9, 2024, 8:00 AM EDT - 8 months ago

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Jul 3, 2024, 3:11 AM EDT - 8 months ago

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 2, 2024, 7:00 PM EDT - 9 months ago

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

May 30, 2024, 4:01 PM EDT - 9 months ago

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 10:00 AM EDT - 10 months ago

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Apr 18, 2024, 1:59 PM EDT - 11 months ago

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Apr 15, 2024, 9:00 AM EDT - 11 months ago

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Apr 4, 2024, 4:00 PM EDT - 11 months ago

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

HireRight Holdings Corp. (HRT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Mar 20, 2024, 10:00 AM EDT - 1 year ago

HireRight Holdings Corp. (HRT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Caribou Biosciences: Under The Radar With Catalysts Approaching

Feb 1, 2024, 8:50 AM EST - 1 year ago

Caribou Biosciences: Under The Radar With Catalysts Approaching

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

Jan 7, 2024, 11:00 AM EST - 1 year ago

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

Dec 12, 2023, 4:02 PM EST - 1 year ago

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

Caribou Biosciences: Upcoming CB-010 Data Could Send The Bears Packing

Nov 26, 2023, 11:42 PM EST - 1 year ago

Caribou Biosciences: Upcoming CB-010 Data Could Send The Bears Packing

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 4:00 PM EST - 1 year ago

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update